Bigger India
Indian drugmakers cashing in on US market as more big-selling drugs gain generic competitors
In the year ending September 2017, the US regulator approved a record 763 generic drugs and expects to sign off on even more rivals for branded drugs in 2018.
The approvals of generic Sensipar (cinacalcet) for Indian firms Cipla and Aurobindo Pharma, while providing for the first generic competition for Sensipar, has turned the spotlight on Indian drug majors investing in the development of complex generics, reports The Pharma Letter’s India correspondent.